Ser171
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser171  -  SET iso2 (human)

Site Information
KDLTKRSsQTQNKAs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 27425001

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 2 ) , immunoassay ( 1 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
leukemia ( 2 ) , T cell leukemia ( 2 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
PRKD2 (human) ( 2 )
Kinases, in vitro:
PRKD2 (human) ( 2 )
Putative upstream phosphatases:
PPP2CA (human) ( 1 )
Treatments:
fingolimod ( 1 ) , Go_6976 ( 2 ) , siRNA ( 2 )

Downstream Regulation
Effects of modification on SET iso2:
enzymatic activity, induced ( 2 ) , molecular association, regulation ( 1 ) , phosphorylation ( 2 )
Effects of modification on biological processes:
signaling pathway regulation ( 1 , 2 )
Inhibit interaction with:
SET iso2 (human) ( 1 )

References 

1

De Palma RM, et al. (2019) The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction. FASEB J, fj201802264R
30917007   Curated Info

2

Irie A, Harada K, Araki N, Nishimura Y (2012) Phosphorylation of SET Protein at Ser171 by Protein Kinase D2 Diminishes Its Inhibitory Effect on Protein Phosphatase 2A. PLoS One 7, e51242
23251465   Curated Info